<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The t(3;21)(q26;q22), which is usually found in blastic crisis of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>-derived <z:hpo ids='HP_0001909'>leukemia</z:hpo>, produces an AML1/EVI-1 fusion protein of 180 kD containing amino-terminal half of AML1 including a <z:mp ids='MP_0001265'>runt</z:mp> homology domain which is fused to the entire of zinc finger EVI-1 protein </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, AML1/EVI-1 fusion protein is a chimeric transcription factor including a <z:mp ids='MP_0001265'>runt</z:mp> homology domain from AML1 and two zinc finger domains from EVI-1, totally three DNA binding domains, and an acidic domain from EVI-1 </plain></SENT>
<SENT sid="2" pm="."><plain>The AML1/EVI-1 fusion protein possesses the dual functions, namely, differentiation block and stimulation of proliferation </plain></SENT>
<SENT sid="3" pm="."><plain>The ability of differentiation block depends on the <z:mp ids='MP_0001265'>runt</z:mp> homology domain in the AML1 part and the effect to stimulate proliferation depends on the second zinc finger domain in the EVI-1 portion </plain></SENT>
<SENT sid="4" pm="."><plain>The AML1/EVI-1 could play an important role in leukemic progression of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> by these dual functions as a transcription factor </plain></SENT>
</text></document>